Quinazolinone derivatives represent a class of heterocyclic compounds that have garnered significant attention in medicinal chemistry due to their diverse pharmacological activities, particularly in the realm of oncology. The compound 7-Methoxy-6-(3-morpholin-4-ylpropoxy)quinazolin-4(3H)-one (CAS: 199327-61-2) stands as a prime example, serving as a crucial intermediate in the synthesis of Gefitinib, a targeted therapy for certain types of non-small cell lung cancer. Understanding the role and procurement of such compounds is vital for researchers and manufacturers alike.

Quinazolinone Core and Therapeutic Significance

The quinazolinone scaffold is a bicyclic structure that forms the basis of many bioactive molecules. Its ability to interact with various biological targets makes it a versatile platform for drug discovery. In the case of Gefitinib, the quinazolinone structure, modified with specific substituents like the methoxy and morpholinopropoxy groups, allows it to selectively inhibit the epidermal growth factor receptor (EGFR) tyrosine kinase. This targeted inhibition disrupts signaling pathways essential for cancer cell proliferation and survival, making it a cornerstone in modern cancer treatment.

Procuring Quinazolinone Derivatives for Research and Manufacturing

For researchers and product development scientists, sourcing high-quality quinazolinone derivatives is a critical step. When looking to purchase 7-Methoxy-6-(3-morpholin-4-ylpropoxy)quinazolin-4(3H)-one, it's important to find suppliers who can guarantee purity and consistency. Pharmaceutical intermediate manufacturers, especially those in China, are key players in providing these complex organic molecules. Buyers often search for terms like 'buy quinazolinone derivative price' or 'Gefitinib intermediate supplier' to identify potential partners. Engaging with a reputable manufacturer ensures access to reliable materials for your R&D projects or large-scale production needs, often at competitive prices.

Future Directions in Quinazolinone Research

The ongoing research into quinazolinone derivatives continues to uncover new therapeutic potentials, ranging from anti-inflammatory and analgesic properties to a broader spectrum of anticancer activities. As the demand for targeted therapies grows, so does the need for efficient and cost-effective synthesis routes, further emphasizing the importance of readily available, high-purity intermediates. By partnering with trusted chemical suppliers, research institutions and pharmaceutical companies can accelerate their discovery and development pipelines.